Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 10/20 | 0.44 |
| ▸ | FABP7 | O15540 | 1/20 | 0.40 |
| ▸ | FABP3 | P05413 | 1/20 | 0.40 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 5/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | THRA | P10827 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3951198 | 0.81 | NAMPT (0.50) | RBP4 | |
| SCHEMBL28086919 | 0.80 | RBP4 (0.42) | RBP4TTRTHRATHRBCHRNA7 | |
| SCHEMBL796697 | 0.80 | MEN1 (0.49) | CHRNA7 | |
| SCHEMBL25190938 | 0.79 | RBP4 (0.57) | RBP4TTR | |
| SCHEMBL20744403 | 0.73 | RBP4 (0.55) | RBP4TTR | |
| SCHEMBL13777973 | 0.71 | SLC6A4 (0.39) | HTR1A | |
| SCHEMBL34475634 | 0.71 | MCHR1 (0.49) | — | |
| SCHEMBL21855171 | 0.71 | AGTR2 (0.51) | — | |
| SCHEMBL20744513 | 0.70 | RBP4 (0.52) | RBP4TTR | |
| SCHEMBL5207932 | 0.70 | RBP4 (0.52) | RBP4TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170828-A1 | Azetidine Derivatives as Inhibitors of Stearoyl-Coenzyme a Delta-9 Desaturase | MERCK FROSST CANADA LTD. (CA) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170828-A1 | Azetidine Derivatives as Inhibitors of Stearoyl-Coenzyme a Delta-9 Desaturase | SCD, SCD5, FASN | RBP4 663/4885FABP7 133/4885FABP3 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.